List of Excipients in Branded Drug OSMOPREP

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	OSMOPREP	sodium phosphate, monobasic, monohydrate, sodium phosphate, dibasic anhydrous	54868-5889	MAGNESIUM STEARATE
Physicians Total Care Inc	OSMOPREP	sodium phosphate, monobasic, monohydrate, sodium phosphate, dibasic anhydrous	54868-5889	POLYETHYLENE GLYCOL 8000
Salix Pharmaceuticals Inc	OSMOPREP	sodium phosphate, monobasic, monohydrate, sodium phosphate, dibasic anhydrous	65649-701	MAGNESIUM STEARATE
Salix Pharmaceuticals Inc	OSMOPREP	sodium phosphate, monobasic, monohydrate, sodium phosphate, dibasic anhydrous	65649-701	POLYETHYLENE GLYCOL 8000

OSMOPREP Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

OSMOPREP is an oral tablet bowel-preparation product built around a high sodium-phosphate load rather than a conventional liquid polyethylene glycol formulation. Its commercial value lies in tablet convenience, low fluid volume relative to large-volume PEG regimens, and potential reformulation opportunities. Its main constraints are renal and cardiovascular safety, tablet burden, sodium and phosphate exposure, and the limited ability of excipients to change the product’s core risk profile.

What is OSMOPREP and how does its formulation work?

OSMOPREP contains sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous. The active salts create an osmotic effect in the gastrointestinal tract that retains water and induces bowel evacuation before colonoscopy.

Product attribute	OSMOPREP
Active ingredients	Sodium phosphate monobasic monohydrate; sodium phosphate dibasic anhydrous
Dosage form	Oral tablets
FDA product type	Prescription drug
FDA application	NDA 021892
Therapeutic use	Colon cleansing before colonoscopy
Formulation category	Osmotic saline bowel preparation
Administration burden	Multiple tablets plus substantial clear-fluid intake
Key safety concern	Acute phosphate nephropathy and fluid/electrolyte abnormalities
Reference product status	OSMOPREP is the branded reference product associated with NDA 021892

The product’s clinical performance depends primarily on the phosphate salts and adequate hydration. Excipients support manufacturability, tablet integrity, disintegration, stability, and patient handling. They do not remove the systemic safety concerns associated with sodium phosphate exposure.

The FDA prescribing information identifies renal injury, electrolyte disturbances, seizures, arrhythmias, and other serious complications as risks associated with oral sodium-phosphate bowel preparations. Risk is higher in patients with renal impairment, older age, dehydration, heart failure, or concomitant use of certain medicines, including diuretics, ACE inhibitors, angiotensin-receptor blockers, and nonsteroidal anti-inflammatory drugs. [1]

What excipients are used in OSMOPREP?

Public labeling identifies microcrystalline cellulose, magnesium stearate, and colloidal silicon dioxide as inactive ingredients in OSMOPREP tablets. [1]

Excipient	Likely formulation function	Commercial and technical relevance
Microcrystalline cellulose	Diluent, compression aid, tablet-bulk material	Supports direct compression but contributes to tablet mass
Magnesium stearate	Lubricant	Reduces sticking and ejection force; excessive levels can slow wetting or dissolution
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and may reduce processing variability

The excipient system is deliberately conventional. A high-load inorganic salt product requires excipients that tolerate a large active-material fraction without compromising tablet hardness, friability, disintegration, or manufacturing throughput.

The formulation challenge is unusual: the product must deliver a large quantity of phosphate salts in a dosage form that remains manufacturable and acceptable to patients. Increasing excipient content can improve compression or handling but increases tablet size and total tablet burden. Reducing excipient content may improve dose density but can worsen capping, lamination, flow, weight variation, and tablet breakage.

How should an OSMOPREP excipient strategy be designed?

The strongest strategy is to treat excipient selection as a dose-density and process-control problem rather than as a conventional taste-masking exercise.

1. Prioritize high-dose tablet manufacturability

Microcrystalline cellulose remains a practical baseline because it supports direct compression and provides compactibility. Commercial development should compare:

• Standard and silicified microcrystalline cellulose
• Co-processed cellulose-based excipients
• Low-moisture grades
• Spray-dried or engineered compressible diluents
• Anhydrous dibasic calcium phosphate, subject to compatibility and regulatory review
• Mannitol or sorbitol where mouthfeel or dissolution performance justifies the added mass

The preferred excipient should provide high compactibility at low concentration. Every reduction in excipient mass can improve tablet size, but poor compactibility can create higher production losses and increase the need for compression force.

2. Control lubricant sensitivity

Magnesium stearate is effective but can create hydrophobicity when over-lubricated. The manufacturing process should control:

• Lubricant concentration
• Blending time
• Shear exposure
• Granule or powder surface area
• Tablet disintegration after accelerated aging

Alternative lubricants, such as sodium stearyl fumarate, may provide a development path where magnesium stearate causes dissolution or disintegration variability. The substitution would require comparative stability, dissolution, impurity, and process-validation work.

3. Minimize moisture-driven instability

Sodium phosphate salts can interact with water during storage and processing. Moisture control is important for:

• Tablet hardness
• Capping and lamination
• Disintegration
• Packaging stability
• Salt hydration-state control
• Weight gain or surface changes during accelerated stability testing

Low-water-activity excipient grades, controlled-humidity compression, and high-barrier packaging can be more commercially valuable than a novel excipient itself.

4. Improve tablet handling

A coating strategy could reduce dust, improve swallowing, and protect tablets during distribution. However, coating adds mass and may delay disintegration. A thin film coating should be evaluated against:

• Disintegration time
• Tablet-to-tablet friction
• Swallowability
• Moisture ingress
• Packaging compatibility
• Patient perception of tablet size

A coating that materially delays dissolution could undermine the bowel-preparation regimen. Enteric protection is generally inconsistent with the intended release profile unless a specific clinical rationale supports it.

5. Avoid unnecessary sweeteners and flavors

Taste masking has limited value for a conventional tablet that is swallowed intact. Sweeteners, flavors, and intense cooling agents may increase regulatory and formulation complexity without addressing the main patient burden, which is the number and size of tablets.

A chewable, dispersible, or orally disintegrating version would create a different product profile but could expose patients to the unpleasant taste of concentrated phosphate salts. Such formats would require careful palatability work and may need stronger taste-masking technology than the current product.

What formulation patents could protect an OSMOPREP follow-on product?

Potential intellectual-property positions would likely focus on the dosage form, manufacturing process, packaging, and administration protocol rather than the basic use of sodium phosphate for bowel cleansing.

High-value formulation claim areas

Claim area	Potential protection	Commercial value
High-dose tablet composition	Defined phosphate-to-excipient ratio, tablet hardness, friability, or disintegration	Protects a manufacturable low-bulk formulation
Coated tablet	Polymer system, coating weight, moisture barrier, or swallowability profile	Supports product differentiation
Modified-release design	Controlled release or staged phosphate delivery	Potentially valuable but clinically difficult
Minitablets or multiparticulates	Same active salts in smaller units	May improve swallowing and dosing flexibility
Packaging system	High-barrier blister, desiccant configuration, or moisture-control package	Protects stability and distribution performance
Manufacturing process	Direct compression, dry granulation, blending sequence, or lubrication control	Can create process-based barriers
Combination regimen	Phosphate preparation with hydration guidance or adjunctive medication	More vulnerable to obviousness and method-of-use challenges
Patient-selection method	Use in a defined lower-risk population	Regulatory and clinical utility may be meaningful, but claim scope can be narrow

The basic active-ingredient concept is unlikely to provide a strong exclusivity platform by itself. A follow-on developer would need claims tied to measurable technical results, such as lower tablet mass, improved disintegration, reduced moisture uptake, improved mechanical strength, or equivalent bowel-cleansing efficacy with improved tolerability.

Patent claims should avoid relying only on routine excipient substitutions. Replacing microcrystalline cellulose with another conventional diluent may face obviousness challenges unless the formulation produces an unexpected result.

What is the Orange Book status of OSMOPREP?

OSMOPREP is associated with FDA NDA 021892. The Orange Book is the controlling source for current listed patents, patent-use codes, and marketing-status information. [2]

For commercial planning, the relevant Orange Book questions are:

1. Whether NDA 021892 remains listed as the reference drug.
2. Whether any active patents are listed against the product.
3. Whether those patents cover composition, formulation, method of use, or another category.
4. Whether patent-use codes restrict a generic applicant’s labeling.
5. Whether the product has any listed exclusivity remaining.
6. Whether the listed product is active, discontinued, or subject to a change in marketing status.

Patent expiration should not be inferred from the product’s original approval date. A formulation patent, method-of-use patent, pediatric exclusivity period, patent-term extension, or later-added listing can produce a different date from the NDA approval date. A formal ANDA strategy would require a current Orange Book review and patent-family analysis.

When does OSMOPREP lose exclusivity?

OSMOPREP’s practical exclusivity depends on the active patent listings and any remaining FDA regulatory exclusivity associated with NDA 021892. Sodium phosphate bowel preparations are not biologics, so biosimilar regulation does not apply. A competing product would generally enter through an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable FDA pathway.

For a generic applicant, the principal certification paths are:

• Paragraph I: no relevant patent information has been submitted.
• Paragraph II: all listed patents have expired.
• Paragraph III: the applicant will wait until listed patent expiry.
• Paragraph IV: the listed patent is invalid, unenforceable, or will not be infringed.

A Paragraph IV notice can trigger patent litigation under the Hatch-Waxman Act. The filing of litigation may create a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and litigation developments. [3]

What generic entry risks exist for OSMOPREP?

The generic risk is moderate from a chemistry perspective but potentially higher from a regulatory and commercial perspective.

Regulatory barriers

An ANDA sponsor would need to address:

• Active-ingredient equivalence
• Strength and dosage-form equivalence
• Tablet dimensions and physical attributes
• Dissolution and disintegration
• Impurity and stability profiles
• Labeling conformity
• Container-closure performance
• Manufacturing reproducibility

The product is a high-dose tablet, which can make direct formulation matching difficult. Even when the active salts are simple, the reference product’s compression behavior, disintegration, and moisture performance may be difficult to reproduce precisely.

Clinical and labeling barriers

A generic sponsor may need to demonstrate that its product can carry the reference labeling without introducing material differences in dosing, hydration requirements, contraindications, or warnings. The safety profile of oral sodium phosphate products creates a low tolerance for differences that could affect exposure or hydration behavior.

Commercial barriers

The product competes against:

• Large-volume PEG-electrolyte solutions
• Low-volume PEG regimens
• Sulfate-based oral solutions
• Sodium picosulfate/magnesium oxide/citric acid products
• Other tablet or capsule bowel preparations

A generic OSMOPREP product would face a limited opportunity if prescribers and endoscopists have shifted toward lower-risk alternatives. Price competition could be severe unless the generic secures favorable payer placement or supplies institutional channels.

How does OSMOPREP compare with competing bowel preparations?

Product category	Main advantage	Main limitation	Excipient opportunity
Sodium-phosphate tablets	Tablet-based administration and low preparation volume	Phosphate and sodium safety burden; high tablet count	Improve tablet size, coating, moisture stability, and handling
PEG-electrolyte solution	Broad clinical familiarity and electrolyte-balanced approach	Large fluid volume and poor palatability for some patients	Flavor systems, concentrated reconstitution, packaging
Low-volume PEG products	Lower fluid burden than traditional PEG	Still requires substantial additional clear liquids	Palatability and concentrated dosage forms
Sulfate-based solutions	Lower active tablet burden than phosphate tablets	Taste, electrolyte, and renal considerations	Flavor masking and dose-concentration technologies
Sodium picosulfate regimens	Small preparation volume and established use	Requires hydration and has electrolyte risks	Flavor, dosing convenience, and packaging

OSMOPREP’s differentiator is the solid dosage form. Its weakness is that the tablet format does not eliminate the hydration requirement and may impose a substantial swallowing burden.

What commercial opportunities exist for OSMOPREP excipients?

Opportunity 1: Lower tablet count

The most valuable formulation objective is reducing the number of tablets without reducing the total therapeutic phosphate dose. Potential approaches include:

• Higher-density compaction
• Minitablet aggregation into larger but more swallowable units
• Bilayer or multilayer tablets
• Improved powder packing
• Co-processed excipients that increase tensile strength at lower use levels

This opportunity is technically difficult because the active load is the dominant source of mass. A meaningful reduction in tablet count may require a different dosage form rather than a simple excipient change.

Opportunity 2: Smaller, smoother tablets

A thinner tablet with a low-friction coating could improve swallowing without changing the active dose. Commercial value may be greater in patients who struggle with large tablets or repeated administration.

Opportunity 3: Moisture-resistant packaging

High-barrier blister packaging, desiccant-integrated bottles, or unit-dose systems could protect product quality and improve adherence. Packaging patents may be easier to differentiate than conventional excipient substitutions if the system demonstrates a measurable stability advantage.

Opportunity 4: Hospital and ambulatory-procedure supply

Institutional customers may value:

• Unit-dose packaging
• Barcode-ready blister cards
• Procedure-specific dose kits
• Hydration instruction cards
• Reduced preparation-room handling
• Compatibility with electronic medication administration systems

These opportunities are commercial rather than purely formulation-based and may support premium pricing even when active ingredients are generic.

Opportunity 5: Lower-risk patient segmentation

A branded follow-on could focus on patients for whom tablet administration is clinically useful and who do not have major phosphate-related risk factors. A narrower label would not eliminate the core safety restrictions, but it could support targeted commercial positioning.

Which excipient suppliers and manufacturers are commercially relevant?

The main supplier opportunity is not limited to a single excipient. It includes high-performance grades that improve compaction, flow, lubrication control, or moisture stability.

Relevant supplier categories include:

• Microcrystalline cellulose manufacturers
• Silicified cellulose suppliers
• Pharmaceutical-grade colloidal silicon dioxide producers
• Alternative lubricant suppliers
• Film-coating polymer manufacturers
• High-barrier blister and bottle manufacturers
• Contract development and manufacturing organizations with high-dose tablet capability

A supplier seeking to enter this market should generate application data specifically for high-load sodium-phosphate tablets. Generic excipient brochures are unlikely to establish differentiation. Useful data would include tablet tensile strength, ejection force, disintegration after humidity exposure, dissolution, friability, and stability in the intended package.

What patent litigation and Paragraph IV risks affect OSMOPREP?

The main litigation risk would arise from any active Orange Book-listed patents associated with NDA 021892. A Paragraph IV filing could challenge patents directed to:

• The sodium-phosphate tablet composition
• A particular excipient ratio
• A coating or release profile
• Packaging or stability features
• A method of colon cleansing
• A dosing schedule or hydration regimen

A follow-on product that uses a materially different formulation may reduce formulation-patent exposure but still face method-of-use issues if its proposed labeling overlaps a listed use code.

Patent strength is likely to be highest where claims include experimentally supported performance limitations. Claims that merely recite common excipients at predictable concentrations are more exposed to invalidity arguments based on obviousness and routine optimization.

Is there biosimilar risk for OSMOPREP?

No. OSMOPREP is a small-molecule drug product, not a biologic. Biosimilar approval under the Public Health Service Act does not apply. Competitive entry would come through generic-drug pathways, an NDA for a differentiated product, or potentially an abbreviated pathway depending on the product’s formulation and regulatory status.

What licensing deals could create value around OSMOPREP?

Potential licensing structures include:

1. Excipient technology license. A supplier licenses a co-processed diluent or lubricant system supported by high-dose phosphate-tablet data.

2. Formulation license. A developer licenses a smaller-tablet, coated-tablet, minitablet, or moisture-stable formulation to a branded gastrointestinal company.

3. Manufacturing-process license. A process owner licenses direct-compression or dry-granulation technology that improves yield and reduces tablet defects.

4. Packaging license. A packaging company licenses a moisture-control blister or unit-dose system.

5. Regional commercial license. A product owner grants rights in markets where sodium-phosphate tablet preparations remain commercially viable.

6. Co-development agreement. A gastrointestinal company funds clinical or human-factors work in return for rights to a differentiated tablet format.

The most defensible deal asset would combine formulation IP, process know-how, stability data, and validated manufacturing capability. A stand-alone excipient substitution has weaker negotiating value unless it reduces cost or produces a clear clinical or manufacturing advantage.

Key Takeaways

• OSMOPREP is a high-dose sodium-phosphate tablet bowel preparation associated with FDA NDA 021892.
• Its labeled inactive ingredients are microcrystalline cellulose, magnesium stearate, and colloidal silicon dioxide.
• The primary excipient challenge is achieving high tablet strength and reliable disintegration while limiting tablet size and count.
• Moisture control, lubricant optimization, thin coating, and high-barrier packaging are the most practical near-term development areas.
• The largest commercial opportunity is a lower-burden solid dosage form, but excipient changes alone may not materially reduce the active-mass requirement.
• OSMOPREP has generic rather than biosimilar risk.
• Paragraph IV exposure depends on the current Orange Book patent listings and patent-use codes for NDA 021892.
• Stronger patent positions would require measurable technical advantages, not routine substitution of one conventional excipient for another.
• Commercial opportunities include formulation licensing, high-dose tablet manufacturing, unit-dose packaging, and institutional bowel-preparation kits.
• The product’s renal and electrolyte safety profile remains the central constraint on market expansion.

FAQs

Can OSMOPREP be reformulated as a smaller tablet?

Potentially, but the active phosphate mass dominates the tablet burden. Higher-density compression, improved excipient efficiency, or a minitablet format may reduce dimensions, while a major reduction in tablet count would likely require a different dosage form.

Would a film coating improve OSMOPREP compliance?

A thin, low-friction coating could improve handling and swallowing. The coating must preserve rapid disintegration and avoid adding substantial mass or moisture sensitivity.

Can an excipient change remove OSMOPREP’s renal warning?

No. The primary renal and electrolyte risks arise from sodium-phosphate exposure, hydration status, and patient characteristics. Excipients may improve handling but do not eliminate those risks.

Is a sodium-phosphate powder a stronger commercial alternative to OSMOPREP tablets?

Not necessarily. A powder may reduce tablet count but can create taste, dosing, reconstitution, and adherence problems. Its value would depend on whether the product improves the patient experience without increasing safety or administration complexity.

What is the best patent strategy for an OSMOPREP follow-on?

The strongest strategy would combine a differentiated composition with process and packaging claims supported by comparative data showing improved tablet strength, reduced size, better moisture stability, faster disintegration, or improved patient handling.

References

1. U.S. Food and Drug Administration. (2023). OSMOPREP (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Guidance for industry: 180-day exclusivity and generic drug patent certifications under the Hatch-Waxman amendments.